NCT04400188View on ClinicalTrials.gov

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

January 15, 2022

Study Completion Date

January 15, 2022

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Fluzoparib

Given PO

DRUG

temozolomide

Given PO

BIOLOGICAL

SHR-1316

Given injection

Trial Locations (1)

610015

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04400188 - A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter